MedWorm: Accupril

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet [Camber Pharmaceuticals]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 15 Dec 2011 05:00:00 +0100

Updated Date: Dec 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDEtablet, Film Coated [Aurobindo Pharma Limited]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 13 Dec 2011 05:00:00 +0100

Updated Date: Dec 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The influence of antihypertensive treatment on arterial stiffness and selected matrix metalloproteinases plasma activity

Artery Research — Thu, 01 Dec 2011 05:00:00 +0100

The aim of the study was to compare the effects of 5 selected drugs on arterial stiffness and matrix metalloproteinases (MMPs) plasma activity in patients with essential arterial hypertension (HT).Material and methods: 95 pts. with HT stage 1 and 2, (N=19 in each treatment group) were treated for 6 months by: quinapril 20-40 mg/d (group-1), amlodipine 5-10mg/d (group-2), hydrochlorothiazide 12,5-25mg/d (group-3), losartan 50-100 mg/d (group 4), bisoprolol 5-10 mg/d (group-5). Before and then after 1,3 and 6 months of treatment office blood pressure (BP) was measured using Omron M5-I device. Carotid femoral pulse wave velocity (PWV) was measured using 3 devices Complior®, Sphygmocor® and ArteriographTM.. Plasma concentration of (MMPs): MMP1, MMP2, MMP3, MMP9 and MMPs tissue inhibitor (TIM...

QUINAPRIL (Quinapril) Tablet [Med Health Pharma, LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 23 Nov 2011 05:00:00 +0100

Updated Date: Nov 23, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

QUINAPRIL (Quinapril) Tablet, Film Coated [Med-Health Pharma, LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 17 Nov 2011 05:00:00 +0100

Updated Date: Nov 17, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ACCURETIC (Quinapril Hydrochloride And Hydrochlorothiazide) Tablet, Film Coated [Parke-Davis Div Of Pfizer Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 26 Oct 2011 05:00:00 +0100

Updated Date: Oct 26, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Greenstone LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 26 Oct 2011 05:00:00 +0100

Updated Date: Oct 26, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The Effect of Quinapril Treatment on Insulin Resistance, Leptin and High Sensitive C-Reactive Protein in Hypertensive Patients.

Clinical and Experimental Hypertension — Thu, 29 Sep 2011 04:00:00 +0100

Authors: Sari F, Eray E, Sari R Abstract The aim of the study was to evaluate the effect of quinapril on HOMA-IR, high sensitive C-reactive protein and leptin. Total 54 hypertensive and 24 control subjects were included in this study. Blood pressure, leptin, high sensitive C-reactive protein, and HOMA-IR were determined at baseline and after 3 months quinapril treatment. After treatment with quinapril HOMA-IR (p = 0.04), high sensitive C-reactive protein (p = 0.027), and leptin (p = 0.046) were decreased in hypertensive patients. Quinapril may be used as a therapy for improving blood pressure as well as the insulin resistant, hyperleptinemic, and low-grade inflammatory state in hypertension. PMID: 21957896 [PubMed - as supplied by publisher] (Source: Clinical and Experimental H...

Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial

Heart — Wed, 07 Sep 2011 04:00:00 +0100

Conclusions Postoperative anaemia is common, frequently persists for months after CABG surgery and is associated with an impaired outcome. In patients with anaemia, ACE inhibitors slowed recovery from postoperative anaemia and increased the incidence of cardiovascular events after CABG. (Source: Heart)

QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDEtablet, Film Coated [Aurobindo Pharma Limited]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 19 Aug 2011 05:00:00 +0100

Updated Date: Aug 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

QUINAPRIL HCL AND HYDROCHLOROTHIAZIDEtablet [GAVIS Pharmaceuticals, LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 18 Jul 2011 05:00:00 +0100

Updated Date: Jul 18, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Pfizer reports prescription drugs stolen

Modern Medicine — Sat, 28 May 2011 20:01:30 +0100

Several lots of azithromycin, Quinapril, and other drugs were stolen in mid-May from Pfizer and its Greenstone subsidiary when a company truck was en route to a CVS store. (Source: Modern Medicine)

Accuretic (Quinapril HCl/Hydrochlorothiazide) - updated on RxList

RxList - New and Updated Drug Monographs — Wed, 11 May 2011 07:00:00 +0100

Accuretic (Quinapril HCl/Hydrochlorothiazide) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

ACCURETIC (Quinapril Hydrochloride And Hydrochlorothiazide) Tablet, Film Coated [Parke-Davis Div Of Pfizer Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 28 Apr 2011 05:00:00 +0100

Updated Date: Apr 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Greenstone LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 28 Apr 2011 05:00:00 +0100

Updated Date: Apr 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Med Health Pharma, LLC.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 28 Apr 2011 05:00:00 +0100

Updated Date: Apr 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Quinapril/simvastatin/spironolactone: Rhabdomyolysis leading to hyperkalaemia and complete AV block: case report

Reactions — Sun, 24 Apr 2011 16:50:04 +0100

(Source: Reactions)

Assessing The Treatment Effect in Metabolic Syndrome without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women.

Current Vascular Pharmacology — Sun, 10 Apr 2011 23:00:00 +0100

Conclusions-Attaining the treatment target of LDL-C<100 mg/dl within multifactorial treatment of MetS by expert clinics, is achievable and beneficial even in patients without diabetes or known CVD. This induces a considerable e-CVD risk reduction in MetS patients. Actual CVD events were negligible, suggesting that e-CVD risk overestimates actual CVD risk in MetS, at least in patients achieving LDL-C<100 mg/dl [ClinicalTrials.gov ID: NCT00416741]. PMID: 21476961 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)

QUINAPRIL HYDROCHLORIDEtablet, Film Coated [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 03 Feb 2011 05:00:00 +0100

Updated Date: Feb 3, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Naproxen/quinapril: Angioedema in an elderly patient: case report

Reactions — Mon, 24 Jan 2011 17:42:36 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 05 Jan 2011 05:00:00 +0100

Updated Date: Jan 5, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice

Diabetologia — Wed, 15 Dec 2010 19:05:07 +0100

Conclusions/interpretation Inhibition of AGE accumulation, using a delayed intervention with alagebrium or pyridoxamine, significantly attenuated the progression of established diabetes-associated atherosclerosis, similar to results obtained with quinapril. These findings provide further evidence that blockade of AGE-mediated pathways may present a novel therapy for the prevention of atherosclerosis in diabetes. Content Type Journal ArticleDOI 10.1007/s00125-010-2000-9Authors A. M. D. Watson, Diabetes Division, Baker IDI Heart & Diabetes Institute, PO Box 6492, St Kilda Road Central, Melbourne, VIC 8008, AustraliaA. Soro-Paavonen, Diabetes Division, Baker IDI Heart & Diabetes Institute, PO Box 6492, St Kilda Road Central, Melbourne, VIC 8008, AustraliaK. Sheehy, ...

Applications and modifications of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid (tic) in peptides and peptidomimetics design and discovery.

Current Protein and Peptide Science — Wed, 01 Dec 2010 00:00:00 +0100

Authors: Zhang Y, Fang H, Xu W Tic, short for 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, is a kind of unnatural α-amino acids. Due to its distinct geometrical conformation and biological activity, the structure of Tic, regarded as the surrogate of proline and the rigid analogue of phenylalanine or tyrosine, has been introduced into many compounds, which target diverse enzymes or receptors. The most successful example is that substituting the Tic residue for the proline residue of enalapril led to an approved drug quinapril. In this review, we will summarize the applications and modifications of Tic in peptides and peptidomimetics design and discovery, and hope to spark medicinal researchers' inspiration in the field of protein and peptide drug design and optimization. PMID:...

ACCUPRIL (Quinapril Hydrochloride) Tablet, Film Coated [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 23 Nov 2010 05:00:00 +0100

Updated Date: Nov 23, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Applications and Modifications of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid (Tic) in Peptides and Peptidomimetics Design and Discovery.

Current Protein and Peptide Science — Thu, 07 Oct 2010 22:45:57 +0100

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

quinapril hcl/hydrochlorothiazide - oral, Accuretic

MedicineNet Cholesterol General — Wed, 22 Sep 2010 07:00:00 +0100

Title: quinapril hcl/hydrochlorothiazide - oral, AccureticCategory: MedicationsCreated: 3/2/2005Last Editorial Review: 9/22/2010 (Source: MedicineNet Cholesterol General)

Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence

NeLM - Disease Focused Reviews — Sun, 22 Aug 2010 23:00:00 +0100

Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This review evaluated the effect of angiotensin-converting enzyme-inhibitor or angiotensin receptor blocker use following kidney transplantation. The authors found that treatment with an angiotensin-converting enzyme-inhibitor or angiotensin receptor blocker produced clinically conflicting results of reductions in proteinuria, haematocrit and glomerular filtration rate in renal transplant recipients. These conclusions seemed sufficiently cautious. [The included interventions were benazapril, candesartan, captopril, enalapril, fosinopril, lisinopril, losartan, perindopril, quinapril, trandolapril and valsartan.] CRD Commentary: The research question was clear with supporting inclusion criteria for participants, interven...

Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction

European Journal of Heart Failure — Fri, 20 Aug 2010 16:10:15 +0100

Conclusion These data show that the use of rosuvastatin plus a standard HF therapy results in a significant additional improvement in HF and cardiac remodelling in a rat model of HFpEF. These beneficial effects were independent of BP and plasma lipid changes, and seem to be due, at least in part, to decreased myocardial inflammation. (Source: European Journal of Heart Failure)

QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDEtablet, Film Coated [Aurobindo Pharma Limited]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 17 Aug 2010 05:00:00 +0100

Updated Date: Aug 17, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Angioedema after nonsteroidal antiinflammatory drug initiation in a patient stable on an angiotensin-converting-enzyme inhibitor.

American Journal of Health-System Pharmacy : AJHP — Mon, 09 Aug 2010 15:27:31 +0100

Conclusion A 68-year-old African-American man who had been receiving quinapril for 5 years developed angioedema after initiation of naproxen. PMID: 20689124 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

Unique case of presumed lisinopril-induced hepatotoxicity.

American Journal of Health-System Pharmacy : AJHP — Mon, 09 Aug 2010 15:27:27 +0100

Conclusion A woman who had received quinapril, enalapril, and lisinopril in the past without apparent adverse effects developed hepatocellular disease that became evident eight months after lisinopril therapy was reinstituted. The presumed hepatotoxicity resolved after discontinuation of lisinopril. PMID: 20689125 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

Effects of ACE Inhibitors on Cardiac Angiotensin II and Aldosterone in Humans: "Relevance of Lipophilicity and Affinity for ACE"

American Journal of Hypertension — Wed, 14 Jul 2010 23:00:00 +0100

ConclusionsThese findings do not support the concept that a hydrophilic ACE inhibitor is less effective in blocking the cardiac RAAS as compared to lipophilic ACE inhibitors.American Journal of Hypertension (2010). doi:10.1038/ajh.2010.148. PMID: 20634797 [PubMed - as supplied by publisher] (Source: American Journal of Hypertension)

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE (Qinapril Hydrochloride And Hydrochlorothiazide) Tablet, Film Coated [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 10 May 2010 05:00:00 +0100

Updated Date: May 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo.

Pharmacological Reports — Fri, 30 Apr 2010 23:00:00 +0100

This study describes a modification of Vane's blood-bathed organ technique (BBOT). This new technique consisted of replacing the cascade of contractile smooth muscle organs within the traditional BBOT by a single collagen strip cut from a rabbit's hind leg tendon. Utilizing the extracorporeal circulation of an anesthetized heparinized mongrel cat or Wistar rat, arterial blood was dripped (1-3 ml min(-1)) over a collagen strip. This resulted in a gain in weight of the strip, which was due to the deposition of platelet aggregates and a few blood cells trapped over the strip. Arterial blood that had been used for the superfusion was pumped back into the animal's venous system. However, when this technique is adapted to human volunteers, the superfusing blood should be discarded. In animal exp...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Greenstone LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 13 Apr 2010 05:00:00 +0100

Updated Date: Apr 13, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess

AJP: Heart and Circulatory Physiology — Fri, 19 Mar 2010 17:01:46 +0100

This study examined the role of the renin-angiotensin-aldosterone system (RAAS) in mediating cardiovascular and renal damage in spontaneously hypertensive rats (SHR) given salt excess. Since the circulating RAAS is inhibited in this model, it permits examination of the role of local tissue RAASs in mediating this injury. To this end, male 8-wk SHR were divided into 7 groups. The control group (C) received normal NaCl (0.6%) diet. All other groups were given 8% NaCl chow. In addition, group 2 was given placebo, group 3 the mineralocorticoid receptor blocker eplerenone (100 mg·kg–1·day–1), group 4 the angiotensin converting enzyme inhibitor quinapril (3 mg·kg–1·day–1), group 5 the angiotensin II type 1 receptor blocker candesartan (10 mg&mi...

ACCURETIC (Quinapril Hydrochloride And Hydrochlorothiazide) Tablet, Film Coated [Parke-Davis Div Of Pfizer Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 24 Feb 2010 05:00:00 +0100

Updated Date: Feb 24, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Greenstone LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 24 Feb 2010 05:00:00 +0100

Updated Date: Feb 24, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: The role of adipocyte-derived angiotensin II.

European Journal of Pharmacology — Fri, 12 Feb 2010 00:00:00 +0100

In this study, we examined the role of adipocyte-generated angiotensin II in PVAT-mediated potentiation of contraction to nerve stimulation. In rat mesenteric PVAT, the presence of angiotesinogen and angiotensin I-converting enzyme (ACE) mRNA was confirmed by RT-PCR. Immunohistochemical staining showed the presence of angiotensin II in mesenteric PVAT. In rat mesenteric arteries, treatment of the vessels with an ACE inhibitor (enalaprilat) or angiotensin II type 1 receptor antagonist (candesartan) reduced PVAT-mediated potentiation of EFS-induced contraction. Exogenously applied angiotensin II enhanced EFS-induced contraction in arteries without PVAT, but not in the arteries with intact PVAT. Chronic treatment with an ACE inhibitor quinapril (14 days) lowered blood pressure and alleviated ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.

American Journal of Physiology. Heart and Circulatory Physiology — Fri, 29 Jan 2010 00:00:00 +0100

This study examined the role of the renin-angiotensin-aldosterone system (RAAS) in mediating cardiovascular and renal damage in SHR given salt-excess. Since the circulating RAAS is inhibited in this model, it permits examination of the role of local tissue RAASs in mediating this injury. To this end, male 8-week SHR rats were divided into 7 groups. The control group (C) received normal NaCl (0.6%) diet. All other groups were given 8% NaCl chow. In addition, Group 2 was given placebo, Group 3 the mineralocorticoid receptor blocker eplerenone (100/mg/day), Group 4 received the ACE-I, quinapril (3 mg/kg/day), Group 5 an ARB candesartan (10 mg/kg/day), and Groups 6 and 7 were given eplerenone and either quinapril or candesartan. The treatments lasted 8 weeks. Compared with controls, mean arter...

Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT)

BMC Pediatrics - Latest articles — Thu, 17 Dec 2009 00:00:00 +0100

DiscussionAdDIT will provide important data on the potential renal and cardiovascular protective effects of ACEI and statins in high-risk adolescents. Long-term follow-up of the randomized subjects will provide direct evidence of disease outcomes, in addition to the data on early surrogate measures of DN and CVD. Follow up of non-randomized low-risk subjects will determine the potential impact of intervention on DN and CVD. AdDIT will help to determine whether, in addition to encouraging young people to achieve good glycaemic control, pharmacological cardio-renal protection should also be implemented.EudraCT Number: 2007-001039-72Trial Registration Number: ISRCTN91419926 (Source: BMC Pediatrics - Latest articles)

Candesartan cilexetil/eprosartan/quinapril: Acute renal failure (first report for eprosartan) in elderly patients: 2 case reports

Reactions — Mon, 07 Dec 2009 14:04:26 +0100

(Source: Reactions)

Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes

Nephrology Dialysis Transplantation — Tue, 24 Nov 2009 09:02:16 +0100

Conclusions. In subtotally nephrectomized rats, mineralocorticoid blockade provided additional renoprotection over and above ACE inhibition. Such benefit was paralleled by major changes in podocyte number and morphology and was not blood pressure dependent. (Source: Nephrology Dialysis Transplantation)

QUINAPRIL HYDROCHLORIDEtablet, Film Coated [Greenstone LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 19 Nov 2009 05:00:00 +0100

Updated Date: Nov 19, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

ACCUPRIL (Quinapril Hydrochloride) Tablet, Film Coated [Parke-Davis Div Of Pfizer Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 19 Nov 2009 05:00:00 +0100

Updated Date: Nov 19, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ACCURETIC (Quinapril Hydrochloride And Hydrochlorothiazide) Tablet, Film Coated [Parke-Davis Div Of Pfizer Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 19 Nov 2009 05:00:00 +0100

Updated Date: Nov 19, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Greenstone LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 19 Nov 2009 05:00:00 +0100

Updated Date: Nov 19, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Effect of Quinapril on In-Stent Restenosis and Relation to Plasma Apoptosis Signaling Molecules

The American Journal of Cardiology — Mon, 16 Nov 2009 00:00:00 +0100

In conclusion, the angiotensin-converting enzyme inhibitor quinapril inhibits in-stent restenosis by stimulating apoptosis after percutaneous intervention. (Source: The American Journal of Cardiology)

Stabilization of quinapril by incorporating hydrogen bonding interactions

Indian Journal of Pharmaceutical Sciences — Wed, 28 Oct 2009 14:05:17 +0100

Roy B N, Singh G P, Godbole H M, Nehate S PIndian Journal of Pharmaceutical Sciences 2009 71(4):395-405In the present study stability of various known solvates of quinapril hydrochloride has been compared with nitromethane solvate. Nitromethane solvate was found to be more stable compared to other known solvates. Single crystal X-ray diffraction analysis of quinapril nitromethane solvate shows intermolecular hydrogen bonding between quinapril molecule and nitromethane. Stabilization of quinapril by forming strong hydrogen bonding network as in case of co-crystals was further studied by forming co-crystal with tris(hydroxymethyl)amino methane. Quinapril free base forms a stable salt with tris(hydroxymethyl)amino methane not reported earlier. Quinapril tris(hydroxymethyl)amino methane salt f...

MedWorm Sponsor Message: Find the best January Sales in the UK.

The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice

Diabetologia — Tue, 27 Oct 2009 17:56:17 +0100

Conclusions/interpretation This study demonstrates that ETA blockade with avosentan may provide an alternate therapeutic strategy for the treatment of diabetic micro- and macrovascular complications. Content Type Journal ArticleCategory ArticleDOI 10.1007/s00125-009-1540-3Authors A. M. D. Watson, Baker IDI Heart and Diabetes Institute PO Box 6492 St Kilda Road Central Melbourne 8008 VIC AustraliaJ. Li, Baker IDI Heart and Diabetes Institute PO Box 6492 St Kilda Road Central Melbourne 8008 VIC AustraliaC. Schumacher, Novartis Pharma Basel SwitzerlandM. de Gasparo, MG Consulting Rossemaison SwitzerlandB. Feng, Baker IDI Heart and Diabetes Institute PO Box 6492 St Kilda Road Central Melbourne 8008 VIC AustraliaM. C. Thomas, Baker IDI Heart and Diabetes Institute PO Box...

Accupril (Quinapril Hydrochloride) - updated on RxList

RxList - New and Updated Drug Monographs — Fri, 09 Oct 2009 07:00:00 +0100

Accupril (Quinapril Hydrochloride) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

Ion pair-HPLC method for the simultaneous estimation of quinapril and hydrochlorothiazide in tablets

Indian Journal of Pharmaceutical Sciences — Fri, 25 Sep 2009 16:24:50 +0100

Gandhimathi M, Ravi T KIndian Journal of Pharmaceutical Sciences 2009 71(3):311-313A simple, precise and rapid HPLC method has been developed and validated for the estimation of quinapril and hydrochlorothiazide simultaneously in combined dosage form. The mobile phase used was a mixture of 0.1% v/v triethylamine (pH 3.5), containing 1 mM of hexane sulphonic acid: acetonitrile (30:70% v/v). The detection of quinapril and hydrochlorothiazide was carried out on photo diode array detector at 220 nm. Results of the analysis were validated statistically and by recovery studies. The proposed method can be successfully used to determine the drug contents of marketed formulation. (Source: Indian Journal of Pharmaceutical Sciences)

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 24 Sep 2009 05:00:00 +0100

Updated Date: Sep 24, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Greenstone LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 02 Jul 2009 05:00:00 +0100

Updated Date: Jul 2, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Sun Pharma USFDA nod for anti hypertensive drug

The Economic Times Healthcare and Biotech News — Fri, 19 Jun 2009 14:39:04 +0100

Sun Pharmaceutical Industries said it has got approval for its Abbreviated New Drug Application for generic version of Quinapril Hydrochloride tablets used in treatment of hypertension and congested heart failure. (Source: The Economic Times Healthcare and Biotech News)

Sex-dependent impairment of cardiac action potential conduction in type 1 diabetic rats

AJP: Heart and Circulatory Physiology — Fri, 01 May 2009 04:00:00 +0100

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEtablet, Film Coated [Ranbaxy Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 02 Apr 2009 05:00:00 +0100

Updated Date: Apr 2, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Ranbaxy Secures Usfda Approval For Quinapril+Hctz Tablets

Health News from Medical News Today — Thu, 19 Mar 2009 11:00:00 +0100

Ranbaxy Laboratories Limited (Ranbaxy), announced that the company has received an approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg. (Source: Health News from Medical News Today)

Gender-Dependent Impairment of Cardiac Action Potential Conduction in Type 1 Diabetic Rats.

American Journal of Physiology. Heart and Circulatory Physiology — Fri, 13 Mar 2009 04:00:00 +0100

In conclusion, the slowing of cardiac impulse propagation in type 1 diabetes is smaller in female rats, partly due to the presence of female sex hormones. This difference is (partly) mediated by gender differences in activation of the cardiac renin-angiotensin system. Key words: Diabetes, gender, impulse propagation, gap junction. PMID: 19286947 [PubMed - as supplied by publisher] (Source: American Journal of Physiology. Heart and Circulatory Physiology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Validated HPTLC method for simultaneous determination of quinapril hydrochloride and hydrochlorothiazide in a tablet dosage form

Indian Journal of Pharmaceutical Sciences — Sat, 20 Dec 2008 09:28:00 +0100

Bhavar Girija B, Chatpalliwar V A, Patil D D, Surana S JIndian Journal of Pharmaceutical Sciences 2008 70(4):529-531Quinapril hydrochloride and hydrochlorothiazide were simultaneously determined by HPTLC in pharmaceutical formulations. The drugs were separated on silica gel 60 F<sub> 254</sub> plates using suitable combination of solvents as mobile phase. The validation parameters, tested in accordance with the requirements of ICH guidelines, prove the suitability of methods. (Source: Indian Journal of Pharmaceutical Sciences)

Determination of quinapril and quinaprilat in human plasma by ultraperformance liquid chromatography-electrospray ionization mass spectrometry.

Biomedical Chromatography : BMC — Mon, 17 Nov 2008 05:00:00 +0100

Authors: Dasandi B, Shah S, A novel, specific and sensitive ultraperformance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed for the simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma. The method involves a simple, one-step extraction procedure coupled with an Acquity UPLCtrade mark BEH C(18 )column (100 x 2.1 mm, i.d., 1.7 microm) with isocratic elution at a flow-rate of 0.2 mL/min and lisinopril as the internal standard. Detection was performed on a triple-quadrupole tandem mass spectrometer in multiple reaction monitoring mode via electrospray ionization. Using 250 microL plasma, the methods were validated over the concentration range 5.010-500.374 ng/mL for quinapril and 10.012-1000 ng/mL for quinaprilat, ...

Amlodipine a safe add-on to quinapril, losartan in hypertension

Inpharma — Mon, 13 Oct 2008 06:58:10 +0100

(Source: Inpharma)

Amlodipine a safe add-on to quinapril, losartan in hypertension.

Inpharma Weekly — Sat, 11 Oct 2008 10:37:18 +0100

Page: 14 (Source: Inpharma Weekly)

Quinaretic(Quinapril Hydrochloride And Hydrochlorothiazide) Tablet [Actavis Totowa LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 28 Jul 2008 05:00:00 +0100

Updated Date: Jul 28, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Quinapril Hydrochloride(Quinapril Hydrochloride) Tablet, Film Coated [Greenstone LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 25 Jul 2008 05:00:00 +0100

Updated Date: Jul 25, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Quinapril Improves Endothelial Function in Postmenopausal Hypertensive Patients

Kidney and Blood Pressure Research — Fri, 27 Jun 2008 15:21:58 +0100

Kidney Blood Press Res 2008;31:226-233 (DOI:10.1159/000141927) (Source: Kidney and Blood Pressure Research)

Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide

HSMN NewsFeed — Wed, 18 Jun 2008 14:43:50 +0100

Ranbaxy Will Market Generic Atorvastatin in the U.S. With 180 Days Exclusivity From Nov. 30, 2011 Agreement Also Resolves Caduet, Accupril Litigation in the US GURGAON, Harayana, India and PRINCETON, N.J., June 18 (HSMN NewsFeed) -- Ranbaxy Laborat... Biopharmaceuticals, Generics, Litigation, LicensingRanbaxy Laboratories, Pfizer, Lipitor (Source: HSMN NewsFeed)

Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction

Journal of Translational Medicine — Thu, 12 Jun 2008 04:00:00 +0100

Conclusions: After myocardial infarction, both BMMNCs and ACE-I reduce the pattern of pro-Ck response, probably contributing to prevent the deterioration of LV function observed in UT rats. (Source: Journal of Translational Medicine)

Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure.

cmaj — Tue, 06 May 2008 04:00:00 +0100

Authors: Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behlouli H, Tu JV BACKGROUND: Existing clinical trial data do not address whether all angiotensin-converting-enzyme (ACE) inhibitors are similarly beneficial in improving survival and reducing the rate of readmission among patients with congestive heart failure. We sought to answer this question using administrative databases from Canada's 3 most populous provinces. METHODS: Using linked hospital discharge and prescription claims databases in Quebec, Ontario and British Columbia, we identified all patients 65 years or older who were admitted to hospital because of congestive heart failure between Jan. 1, 1998, and Mar. 31, 2002, and who had not been admitted for the same reason in the 3 years preceding the study period. We an...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis.

Nature Clinical Practice. Rheumatology. — Tue, 06 May 2008 04:00:00 +0100

Authors: Guiducci S, Cerinic MM Gliddon et al. conducted a randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy of the angiotensin-converting enzyme inhibitor quinapril for the management of vascular damage in systemic sclerosis (SSc). The trial comprised 213 patients with limited cutaneous SSc or Raynaud's phenomenon (mean age 54 years, 182 females) who were randomly assigned to receive 80 mg/day, or the maximum tolerated dose, of quinapril (n = 105) or placebo (n = 108) for 2-3 years. Patients were assessed every 3 months. The number of new ischemic digital ulcers was recorded as the primary end point, while the frequency of Raynaud's phenomenon episodes, skin score, health status, pulmonary artery pressure and treatments for ischemia were also mon...

Quinapril Hydrochloride(Quinapril Hydrochloride) Tablet, Film Coated [GENPHARM ULC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Sat, 26 Apr 2008 07:03:17 +0100

Updated Date: Apr 25, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Quinapril(Quinapril Hydrochloride) Tablet, Film Coated [Actavis Totowa LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 25 Mar 2008 05:00:00 +0100

Updated Date: Mar 25, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Impact of previous percutaneous transluminal coronary angioplasty and/or stenting revascularization on outcomes after surgical revascularization: insights from the imagine study

European Heart Journal — Sat, 01 Mar 2008 05:00:00 +0100

Conclusion Patients with left ventricular ejection fraction ≥40% having a history of PCI prior to surgery had a worse outcome post-CABG than those with no prior PCI. Further studies are needed to investigate whether these results apply for drug eluting stents. (Source: European Heart Journal)

Angiotensin converting enzyme inhibition enhances collateral artery remodeling in rats with femoral artery occlusion.

The American Journal of the Medical Sciences — Sat, 01 Mar 2008 05:00:00 +0100

Authors: Ren J, Li H, Prior BM, Yang HT Evidence from experimental animal studies indicate that ACE inhibition expands collateral blood flow both in ischemic hearts and peripheral limbs. The present study evaluates whether ACE inhibitor induces collateral blood flow expansion and change of angiogenic gene expression profile in collateral arteries during remodeling. Male Sprague-Dawley rats, weighing 350 g were treated with vehicle (control) or quinapril (ACE inhibitor) at either low dose (3.0 mg/kg) or high dose (18 mg/kg) for 1, 3, 7, 14 days (gene expression) or 16 days (blood flow). All rats received bilateral occlusions of the femoral arteries. Collateral blood flow to the hind limb was assessed by 85Sr and 141Ce-labeled microspheres during treadmill running at 15 and 25 m/min spee...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Quinapril Hydrochloride(Quinapril Hydrochloride) Tablet, Film Coated [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 15 Feb 2008 05:00:00 +0100

Updated Date: Feb 15, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Comparison of Selective AT1-Receptor Blockade Versus ACE Inhibition for Restenosis Prophylaxis in Patients With Peripheral Occlusive Arterial Disease After Stent Angioplasty: A Randomized, Controlled, Proof-of-Concept Study

Angiology — Wed, 23 Jan 2008 05:00:00 +0100

This study revealed significant benefit of a pharmacological restenosis regimen using the AT1-receptor antagonist candesartan in patients with severe atherosclerosis after superficial femoral artery stenting compared with treatment with the ACE inhibitor quinapril. Further prospective studies in patients are required to confirm these results. (Source: Angiology)

Early initiation of ACEIs in low-risk patients after coronary artery bypass surgery of no benefit?

NeLM Headline News — Wed, 12 Dec 2007 00:00:00 +0100

According to research published early online in Circulation, routine early initiation of angiotensin-converting enzyme inhibitor (ACEI) therapy does not appear to improve clinical outcome up to 3 years after coronary artery bypass surgery (CABG), but does increase the incidence of adverse events, particularly after CABG. The Ischaemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme (IMAGINE) trial investigated whether early initiation (</= 7 days) of an ACEI after CABG reduced cardiovascular events in stable patients with left ventricular ejection fraction >/= 40%. The double-blind placebo controlled trial involved 2553 patients who were randomised to receive either quinapril to a target dose of 40mg/day or placebo, and patients were followed up fo...

Quinapril Fails to Prevent Vascular Damage in Scleroderma

Medscape Dermatology Headlines — Mon, 10 Dec 2007 21:52:52 +0100

The long-acting angiotensin-converting enzyme (ACE) inhibitor quinapril does not appear to prevent upper limb digital ulcers or other vascular manifestations in patients with limited cutaneous systemic sclerosis (lcSSc), according to UK researchers. Reuters Health Information (Source: Medscape Dermatology Headlines)

Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery.

Circulation — Mon, 10 Dec 2007 05:00:00 +0100

Conclusions-In patients at low risk of cardiovascular events after CABG, routine early initiation of angiotensin-converting enzyme inhibitor therapy does not appear to improve clinical outcome up to 3 years after CABG; however, it increases the incidence of adverse events, particularly early after CABG. Thus, early after CABG, initiation of angiotensin-converting enzyme inhibitor therapy should be individualized and continually reassessed over time according to risk. PMID: 18071079 [PubMed - as supplied by publisher] (Source: Circulation)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiogensin-converting enzyme inhibition

AJP: Endocrinology and Metabolism — Fri, 07 Dec 2007 05:00:00 +0100

Acute physiological hyperinsulinemia increases skeletal muscle capillary blood volume (CBV), presumably to augment glucose and insulin delivery. We hypothesized that insulin-mediated changes in CBV are impaired in type 2 diabetes mellitus (DM) and are improved by angiotensin-converting enzyme inhibition (ACE-I). Zucker obese diabetic rats (ZDF, n = 18) and control rats (n = 9) were studied at 20 wk of age. One-half of the ZDF rats were treated with quinapril (ZDF-Q) for 15 wk prior to study. CBV and capillary flow in hindlimb skeletal muscle were measured by contrast-enhanced ultrasound (CEU) at baseline and at 30 and 120 min after initiation of a euglycemic hyperinsulinemic clamp (3 mU·min–1·kg–1). At baseline, ZDF and ZDF-Q rats were hyperglycemic and hyperinsul...

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

American Journal of Kidney Diseases — Wed, 28 Nov 2007 01:08:21 +0100

CONCLUSIONS: Celecoxib, 200 mg/d, for 6 weeks did not alter proteinuria. Few adverse events were noted in this high-risk population. PMID: 18037095 [PubMed - in process] (Source: American Journal of Kidney Diseases)

Differences in the Effect of Angiotensin-converting Enzyme Inhibitors on the Rate of Endothelial Cell Apoptosis: In Vitro and In Vivo Studies

Cardiovascular Drugs and Therapy — Thu, 15 Nov 2007 20:53:20 +0100

Conclusion Our experiments suggest differences between ACE inhibitors in terms of inhibition of endothelial apoptosis in vivo. Content Type Journal ArticleDOI 10.1007/s10557-007-6068-5Authors C. Ceconi, University of Ferrara Department of Cardiology Corso Giovecca 203 44100 Ferrara ItalyG. Francolini, Foundation Salvatore Maugeri IRCCS Cardiovascular Pathophysiology Research Center Gussago ItalyD. Bastianon, Foundation Salvatore Maugeri IRCCS Cardiovascular Pathophysiology Research Center Gussago ItalyG.L. Gitti, Foundation Salvatore Maugeri IRCCS Cardiovascular Pathophysiology Research Center Gussago ItalyL. Comini, Foundation Salvatore Maugeri IRCCS Cardiovascular Pathophysiology Research Center Gussago ItalyR. Ferrari, University of Ferrara Department of Cardiology C...

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

Arthritis and Rheumatism — Mon, 29 Oct 2007 04:00:00 +0100

To evaluate the efficacy and tolerability of prolonged administration of quinapril, a long-acting angiotensin-converting enzyme inhibitor, in the management of the peripheral vascular manifestations of limited cutaneous systemic sclerosis (lcSSc) and in the prevention of the progression of visceral organ involvement in the disease.This was a multicenter, randomized, double-blind, placebo-controlled study evaluating quinapril 80 mg/day, or the maximum tolerated dosage, in 210 patients with lcSSc or with Raynaud's phenomenon (RP) and the presence of SSc-specific antinuclear antibodies. Treatment was for 2-3 years. The primary outcome measure was the number of new ischemic ulcers appearing on the hands; secondary measures were the frequency and severity of RP attacks, skin score, treatments f...

Does blockade of the Renin Angiotensin system affect sympathetic and blood pressure responses to amlodipine in young hypertensive patients?

American Journal of Hypertension — Wed, 24 Oct 2007 23:46:19 +0100

CONCLUSIONS: It appears that amlodipine does not activate the renin-angiotensin system to counteract its BP-lowering effect in young hypertensives. Similarly, no angiotensin II-dependent component in MSNA appears to be present at baseline or to be induced by amlodipine. PMID: 17954368 [PubMed - in process] (Source: American Journal of Hypertension)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiogensin converting enzyme inhibition.

Am J Physiol Endocri... — Tue, 02 Oct 2007 04:00:00 +0100

SKELETAL MUSCLE CAPILLARY RESPONSES TO INSULIN ARE ABNORMAL IN LATE-STAGE DIABETES AND ARE RESTORED BY ANGIOGENSIN CONVERTING ENZYME INHIBITION. Am J Physiol Endocrinol Metab. 2007 Oct 2; Authors: Clerk LH, Vincent MA, Barrett E, Lankford MF, Lindner JR Acute physiologic hyperinsulinemia increases skeletal muscle capillary blood volume (CBV), presumably in order to augment glucose and insulin delivery. We hypothesized that insulin-mediated changes in CBV are impaired in type-2 diabetes mellitus (DM) and are improved by angiotensin converting enzyme inhibition (ACE-I). Zucker obese diabetic rats (ZDF, n=18) and control rats (n=9) were studied at 20 weeks of age. Half of the ZDF rats were treated with quinapril (ZDF-Q) for 15 weeks prior to study. CBV and capillary flow in hindli...

Effects of 2 Years Treatment with Quinapril on Carotid Intima Media in Type 1 Diabetes Mellitus.

High Blood Pressure & Cardiovascular Prevention — Sat, 29 Sep 2007 00:24:34 +0100

Page: 145Authors: Whisstock, C; Viscardi, L; Bianchi, F; Galbiati, M; Capra, A; Gamba, P L; Paleari, F; Giannattasio, C; Mancia, G (Source: High Blood Pressure & Cardiovascular Prevention)

Degradation mechanism for a trace impurity in quinapril drug by tandem mass and precursor ions studies.

Rapid Communications in Mass Spectrometry : RCM — Tue, 25 Sep 2007 02:48:27 +0100

Authors: Shinde V, Trivedi A, Upadhayay PR, Gupta NL, Kanase DG, Chikate RC PMID: 17708525 [PubMed - in process] (Source: Rapid Communications in Mass Spectrometry : RCM)

The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model.

Nephron Experimental Nephrology — Thu, 06 Sep 2007 01:24:35 +0100

CONCLUSION: In angiotensin-converting enzyme inhibitor-treated SNX animals, abrogation of sympathetic overactivity provides additional renoprotection and less nitro-oxidative stress of podocytes than single interventions. The added benefits were partially blood pressure independent. PMID: 17347582 [PubMed - indexed for MEDLINE] (Source: Nephron Experimental Nephrology)

FDA approves Teva's generic hypertension drug

bizjournals.com Health Care:Pharmaceuticals headlines — Mon, 27 Aug 2007 16:41:00 +0100

Teva Pharmaceutical Industries Ltd. has received Food and Drug Administration approval to market a generic version of Pfizer's Accupril drug for hypertension. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Quinapril for Treatment of Hypertension in Turkey: Dose Titration and Diuretic Combination Treatment Strategies

Clinical Drug Investigation — Wed, 22 Aug 2007 12:59:39 +0100

(Source: Clinical Drug Investigation)

Quinapril for Treatment of Hypertension in Turkey: Dose Titration and Diuretic Combination Treatment Strategies.

Clinical Drug Investigation — Wed, 22 Aug 2007 01:04:00 +0100

Page: 613Authors: Yener, Gul 1; Aran, Sinan 2; Bahceci, Mithat 3; Ozdemir, Kurtulus 4; Gultekin, Fusun 5; Lowe, Wing 6 (Source: Clinical Drug Investigation)

Quinaretic(Quinapril Hydrochloride And Hydrochlorothiazide) Tablet [Actavis Totowa LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Aug 2007 05:00:00 +0100

Updated Date: Aug 15, 2007 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Influence of enalapril, quinapril and losartan on lipopolysaccharide (LPS)-induced serum concentrations of TNF-alpha, IL-1beta, IL-6 in spontaneously hypertensive rats (SHR).

Pharmacological Reports — Sun, 01 Jul 2007 04:00:00 +0100

Authors: Andrzejczak D, Górska D, Czarnecka E Immunopharmacological studies of drugs used in cardiovascular diseases provide new data concerning their modulating effect on the levels of proinflammatory cytokines, chemokines and adhesion molecules. Therefore, we have made an attempt to find out whether enalapril, quinapril and losartan (drugs used in the treatment of arterial hypertension) are able to modulate lipopolysaccharide (LPS)-induced proinflammatory cytokine serum concentrations (tumor necrosis factor alpha - TNF-alpha, interleukin-1beta _ IL-1beta, interleukin-6 - IL-6) in spontaneously hypertensive rats (SHR). The animals were divided into four groups as follows: SHR + M (control rats receiving 1% solution of methylcellulose), SHR + E (rats receiving enalapril - 10 mg/kg...

Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure

AJP: Heart and Circulatory Physiology — Mon, 11 Jun 2007 04:00:00 +0100

This study sought to determine whether ACE inhibitors can directly regulate MMP activity and whether this results in positive structural and functional adaptations to the heart. To this end, MMP-2 activity in LV tissue extracted from rats with an aortocaval (AV) fistula was assessed by in vitro incubation as well as in vivo treatment with captopril, lisinopril, or quinapril. Furthermore, LV size and function were determined in untreated AV fistula rats, AV fistula rats treated with lisinopril (3, 5, and 8 wk), and age-matched sham-operated controls. In vitro incubation with captopril, lisinopril, or quinapril significantly reduced MMP-2 activity, as did in vivo treatment. This occurred without a reduction in the available pool of MMP-2 protein. Long-term in vivo administration of lisinopri...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Quinapril Hydrochloride And Hydrochlorothiazide(Quinapril Hydrochloride And Hydrochlorothiazide) Tablet, Film Coated [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 22 May 2007 05:00:00 +0100

Updated Date: May 22, 2007 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Anti-inflammatory Actions of Quinapril

Cardiovascular Drugs and Therapy — Tue, 03 Apr 2007 09:04:18 +0100

Conclusion Quinapril, which is a potent and selective inhibitor of both plasma and tissue ACE, has demonstrated anti-inflammatory properties in many disease states such as atherosclerosis, nephritis, scleroderma, diabetes and arthritis, and, thus, offers new therapeutic possibilities for disease treatment. Content TypeJournal Article JournalCardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy)

Mylan Announces Launch of Quinapril Tablets, USP and Quinapril Hydrochloride and Hydrochlorothiazide Tablets

Drug Newswire — Mon, 12 Mar 2007 16:58:11 +0100

PITTSBURGH, Feb. 28 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that Mylan Pharmaceuticals Inc. has launched Quinapril Tablets USP, 5mg, 10mg, 20mg and 40mg strengths, and Quinapril Hydrochloride (HCl) and Hydrochlorothiazide (HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg strengths. Quinapril Tablets and Quinapril HCl and HCTZ Tablets are... (Source: Drug Newswire)

The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction

Vascular Medicine recent issues — Thu, 15 Feb 2007 05:00:00 +0100

In conclusion, treatment with quinapril, in combination with sildenafil, improved ED in men with suboptimal response to sildenafil alone. Atorvastatin demonstrated a trend toward improved ED in this group. (Source: Vascular Medicine recent issues)

Flecainide/quinapril overdose: Tachycardia and hypotension: case report

Reactions — Wed, 31 Jan 2007 10:25:03 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Flecainide/quinapril overdose: Tachycardia and hypotension: case report.

Reactions Weekly — Sat, 27 Jan 2007 05:39:02 +0100

(Source: Reactions Weekly)

Clearance of Imidapril, an Angiotensin-Converting Enzyme Inhibitor, During Hemodialysis in Hypertensive Renal Failure Patients: Comparison With Quinapril and Enalapril

The Journal of Clinical Pharmacology — Tue, 23 Jan 2007 07:00:00 +0100

The dialyzability of imidaprilat, an active metabolite of the angiotensin-converting enzyme (ACE) inhibitor imidapril, was determined and compared with those of enalaprilat and quinaprilat in hypertensive patients on chronic hemodialysis. Imidapril (5 mg/d, n = 6), enalapril (2.5 mg/d, n = 6), or quinapril (2.5 mg/d, n = 6) was given for at least 8 weeks prior to the trial. During dialysis, enalaprilat, but not imidaprilat or quinaprilat, concentrations in both sides decreased significantly. Compared to enalaprilat, the dialyzabilities of imidaprilat and quinaprilat were significantly lower (dialyzer clearance [mL/min/m2]: enalaprilat, 41.8 ± 7.4; imidaprilat, 19.0 ± 7.8; quinaprilat, 8.9 ± 1.3). The dialyzabilities of the 3 drugs were negatively correlated with their ...

Cardiorenal protective effects of year-long antihypertensive therapy with a Angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.

American Journal of Hypertension — Fri, 15 Dec 2006 08:32:02 +0100

CONCLUSIONS: It is suggested that year-long antihypertensive therapy with an angiotensin-converting enzyme (ACE) inhibitor is superior to a calcium channel blocker in terms of cardiorenal protection in SHR. PMID: 17161768 [PubMed - in process] (Source: American Journal of Hypertension)

Atorvastatin and quinapril affect coagulation in patients with CAD

Inpharma — Mon, 11 Dec 2006 04:05:02 +0100

(Source: Inpharma)

Long-term organ protection by doxazosin and/or quinapril as antihypertensive therapy.

Journal of Nephrology — Fri, 01 Dec 2006 16:29:03 +0100

Conclusions:Blood pressure control with a high quinapril dose provided higher organ protection than a combined therapy with a lower quinapril dose. This effect was not due to a deleterious effect of doxazosin. PMID: 17136686 [PubMed - in process] (Source: Journal of Nephrology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

The role of central vasopressin receptors in the modulation of autonomic cardiovascular controls: a spectral analysis study

AJP: Regulatory, Integrative and Comparative Physiology — Fri, 03 Nov 2006 07:00:00 +0100

Although it has been suggested that vasopressin (VP) acts within the central nervous system to modulate autonomic cardiovascular controls, the mechanisms involved are not understood. Using nonpeptide, selective V1a, V1b, and V2 antagonists, in conscious rats, we assessed the roles of central VP receptors, under basal conditions, after the central application of exogenous VP, and after immobilization, on cardiovascular short-term variability. Equidistant sampling of blood pressure (BP) and heart rate (HR) at 20 Hz allowed direct spectral analysis in very-low frequency (VLF-BP), low-frequency (LF-BP), and high-frequency (HF-BP) blood pressure domains. The effect of VP antagonists and of exogenous VP on body temperature (Tb) was also investigated. Under basal conditions, V1a antagonist increa...

Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy

Journal of Thrombosis and Haemostasis — Mon, 16 Oct 2006 16:23:23 +0100

Journal of Thrombosis and Haemostasis Volume 4, Issue 11, Page 2397-2404, Nov 2006. (Source: Journal of Thrombosis and Haemostasis)

Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following a 28-day therapy

Journal of Thrombosis and Haemostasis — Mon, 14 Aug 2006 12:42:55 +0100

Journal of Thrombosis and Haemostasis Volume 0, Issue ja. (Source: Journal of Thrombosis and Haemostasis)

Lupin Receives Final Approval for Quinapril Tablets

Drug Newswire — Wed, 28 Jun 2006 06:00:00 +0100

BALTIMORE, June 26 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quinapril Tablets USP in 5 mg, 10 mg, 20 mg and 40 mg strengths. Lupin's Quinapril... (Source: Drug Newswire)

Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats.

J Physiol Pharmacol — Wed, 14 Jun 2006 06:00:00 +0100

In conclusion, given in equipotent hypotensive doses, tissue ACE-Is exerted more pronounced antithrombotic effect than plasma ACE-Is in experimental thrombosis. The differences between tissue and plasma ACE-Is in terms of their more pronounced inhibition of experimental thrombosis may be related to the intensified activation of fibrinolysis and inhibition of coagulation. PMID: 16845228 [PubMed - in process] (Source: J Physiol Pharmacol)

MedWorm Sponsor Message: Find the best January Sales in the UK.